RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Transcode Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.70+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $1.63M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 103.8% | -833.5% | |
| Return on assets | – | – | -40.9% | |
| Current ratio | – | 2.05 | 6.29 | |
| Interest coverage | – | -1.8× | -4229.2× | |
| Diluted shares | – | 0M | 1M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Transcode Therapeutics generated $71.96M from operations and spent $419.77K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$71.96M
Used
$419.77K
Capital expenditure$419.77K100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$34.66M
- Cash generatingOperating cash flow above zero-$19.52M
- Return on assets improvedROA up on the prior year-324.1% → -475.2%
- Earnings backed by cashOperating cash flow above net income-$19.52M vs -$34.66M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.56 → 6.29
- No dilutionShare count did not rise0M → 1M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –